Research programme: BET bromodomain inhibitors - ConverGene

Drug Profile

Research programme: BET bromodomain inhibitors - ConverGene

Alternative Names: CVG201 programme

Latest Information Update: 22 Jan 2017

Price : $50

At a glance

  • Originator ConverGene; National Center for Advancing Translational Sciences
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Bromodomain and extraterminal domain protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 13 Dec 2016 Preclinical trials in Cancer in USA (PO)
  • 13 Dec 2016 ConverGene enters into exclusive licensing agreement with National Center for Advancing Translational Sciences (NCATS) for development of BET bromodomain inhibitors programme
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top